Premium
DNA‐methylation analysis identifies the E‐cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies
Author(s) -
Seidl Sonja,
Ackermann Jutta,
Kaufmann Hannes,
Keck Andrea,
Nösslinger Thomas,
Zielinski Christoph C.,
Drach Johannes,
ZöchbauerMüller Sabine
Publication year - 2004
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.20295
Subject(s) - monoclonal gammopathy of undetermined significance , methylation , dna methylation , cancer research , multiple myeloma , monoclonal , microbiology and biotechnology , medicine , biology , gene , monoclonal antibody , immunology , antibody , genetics , gene expression
BACKGROUND Silencing of tumor suppressor genes (TSG) by aberrant methylation (referred to as methylation ) contributes to the pathogenesis of various human malignancies. However, little is known about the methylation of known and putative TSGs in monoclonal gammopathies. Thus, the authors investigated the methylation frequencies of 10 genes in patients with monoclonal gammopathies. METHODS The methylation patterns of the genes p16 INK4a ( p16 ), tissue inhibitor of metalloproteinase 3 ( TIMP3 ), p15 INK4b ( p15 ), E‐cadherin ( ECAD ), death‐associated protein kinase ( DAPK ), p73 , RAS‐association domain family 1A ( RASSF1A ), p14 , O 6 ‐methylguanine DNA methyltransferase ( MGMT ), and retinoid acid receptor β2 ( RARβ ) were determined in patients with monoclonal gammopathy of undetermined significance (MGUS; n = 29), smoldering multiple myeloma (SMM; n = 5), multiple myeloma (MM; n = 113), or plasma cell leukemia (PCL; n = 7) by methylation‐specific polymerase chain reaction analysis. RESULTS Methylation frequencies for p16 , TIMP3 , p15 , ECAD , DAPK , p73 , RASSF1A , p14 , MGMT , and RARβ were as follows: 28%, 35%, 10%, 0%, 17%, 21%, 14%, 14%, 7%, and 0%, respectively, in patients with MGUS and 36%, 29%, 27%, 27%, 22%, 15%, 15%, 9%, 4%, and 0%, respectively, in patients with MM. Methylation of at least 1 of these genes was detected in 79% of patients with MGUS and in 80% of patients with MM. Although methylation of ECAD was not detected in patients with MGUS, it was observed frequently in patients with MM and with even greater frequency in patients with PCL. It is noteworthy that an association was found between ECAD methylation and poor prognostic markers in patients with MM. CONCLUSIONS Methylation of certain genes can be detected frequently in patients with monoclonal gammopathies. The current data suggest that methylation of ECAD is a marker of disease progression in patients with MM and PCL. Cancer 2004. © 2004 American Cancer Society.